

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 0690)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 23 JUNE 2017

All the resolutions as set out in the notice of AGM were duly passed by way of a poll at the AGM held on 23 June 2017.

Reference is made to the circular of Uni-Bio Science Group Limited (“**Company**”) dated 28 April 2017 in relation to the grant of general mandate to issue and repurchase securities, proposed re-election of directors of the Company, re-appointment of auditors (“**Circular**”). Unless otherwise specified, terms used in this announcement shall have the same meanings as those defined in the Circular.

The Board is pleased to announce that all the resolutions set out in the notice of Annual General Meeting dated 28 April 2017 (“**AGM Notice**”) were duly passed by the Shareholders by way of poll at the Annual General Meeting. As at the date of the Annual General Meeting, there were a total of 5,137,488,147 Shares in issue. None of the Shareholders were required to abstain from voting in favour of any of the resolutions proposed at the Annual General Meeting. As such, there were a total of 5,137,488,147 Shares, representing 100% of the issued share capital of the Company as at the date of the Annual General Meeting, entitling Shareholders to attend and vote for or against the resolutions at the Annual General Meeting. None of the Shareholders were entitled to attend and vote only against the resolutions at the Annual General Meeting.

Full text of the resolutions is set out in the AGM Notice. The poll results for those resolutions are as follows:

ORDINARY RESOLUTIONS		NUMBER OF SHARES (%)	
		FOR	AGAINST
1.	To receive and approve the audited consolidated financial statements and the reports of the directors and auditors of the Company for the year ended 31 December 2016.	2,759,525,286 (100.00%)	0 (0.00%)

* For identification purpose only

ORDINARY RESOLUTIONS		NUMBER OF SHARES (%)	
		FOR	AGAINST
2.	(i) To re-elect, each separate resolution, the following directors of the Company:		
	(a) Mr. Kingsley Leung;	2,759,525,286 (100.00%)	0 (0.00%)
	(b) Mr. Chow Kai Ming;	2,759,525,286 (100.00%)	0 (0.00%)
	(c) Mr. Chen Dawei.	2,759,525,286 (100.00%)	0 (0.00%)
	(ii) To authorise the Board to fix the Directors' remuneration.	2,759,525,286 (100.00%)	0 (0.00%)
3.	To re-appoint Deloitte Touche Tohmatsu as the Company's auditors and authorise the board of directors of the Company to fix its remuneration.	2,759,525,286 (100.00%)	0 (0.00%)
4.	To grant a general mandate to the directors of the Company to allot, issue and otherwise deal with the Company's shares.	2,759,525,286 (100.00%)	0 (0.00%)
5.	To grant a general mandate to the directors of the Company to repurchase the Company's shares.	2,759,525,286 (100.00%)	0 (0.00%)
6.	To add the nominal amount of the Shares repurchased by the Company to the mandate granted to the directors of the Company under resolution numbered 4.	2,759,525,286 (100.00%)	0 (0.00%)

Note: The number of votes and percentage of the voting as stated above are based on the total number of Shares held by the Shareholders who attended and voted at the Annual General Meeting in person, by corporate representative or by proxy.

Tricor Abacus Limited, the Hong Kong branch share registrar and transfer office of the Company, was appointed as the scrutineer for the vote-taking at the Annual General Meeting.

By Order of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 23 June 2017

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Kingsley Leung (Chairman) and Mr. Chen Dawei (Vice-Chairman); and three independent non-executive Directors, namely, Dr. Carl Aslan Jason Morton Firth, Mr. Zhao Zhi Gang and Mr. Chow Kai Ming.